Hims & Hers Health, Inc. (NYSE:HIMS) Insider Soleil Boughton Sells 2,343 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,343 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $29.90, for a total value of $70,055.70. Following the completion of the transaction, the insider now directly owns 165,254 shares in the company, valued at $4,941,094.60. This trade represents a 1.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, October 29th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The stock was sold at an average price of $23.16, for a total value of $54,171.24.
• On Tuesday, October 15th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.41, for a total value of $47,738.99.
• On Tuesday, September 17th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The shares were sold at an average price of $16.50, for a total value of $38,593.50.
• On Tuesday, September 3rd, Soleil Boughton sold 2,345 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.65, for a total value of $34,354.25.

Hims & Hers Health Stock Down 2.2 %

Shares of HIMS opened at $30.67 on Wednesday. The business has a 50-day simple moving average of $20.85 and a two-hundred day simple moving average of $19.44. The stock has a market cap of $6.70 billion, a price-to-earnings ratio of 69.69 and a beta of 1.06. Hims & Hers Health, Inc. has a 52 week low of $8.09 and a 52 week high of $31.68.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. During the same quarter in the prior year, the business posted ($0.04) earnings per share. The business’s quarterly revenue was up 77.1% on a year-over-year basis. On average, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Institutional Trading of Hims & Hers Health

Several institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its position in shares of Hims & Hers Health by 1.0% during the first quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock worth $221,379,000 after purchasing an additional 136,907 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Hims & Hers Health by 113.1% during the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after purchasing an additional 3,205,108 shares in the last quarter. State Street Corp grew its position in shares of Hims & Hers Health by 4.7% during the third quarter. State Street Corp now owns 4,626,543 shares of the company’s stock worth $85,221,000 after purchasing an additional 206,078 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Hims & Hers Health by 12.7% during the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock worth $79,029,000 after purchasing an additional 482,177 shares in the last quarter. Finally, Wellington Management Group LLP grew its position in shares of Hims & Hers Health by 34.5% during the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock worth $63,446,000 after purchasing an additional 883,230 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on HIMS. Canaccord Genuity Group upped their price target on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Piper Sandler reaffirmed a “neutral” rating and issued a $21.00 price target (up from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Bank of America downgraded Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their target price for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Deutsche Bank Aktiengesellschaft boosted their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Finally, Needham & Company LLC began coverage on Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $20.71.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.